Kidney PATIENT Act of 2023

Bill: 118-hr-5074
Sponsor: full_name: Rep. Carter, Earl L. "Buddy" [R-GA-1]
Introduced: 2023-07-28
Policy area: Health
Subjects: Digestive and metabolic diseases

Health care costs and insurance

Medicare

Prescription drugs
Latest action: action_date: 2024-06-11
text: Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-548, Part I.

Summaries:
action_date: 2023-07-28
action_desc: Introduced in House
text: <p><b>Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 or the Kidney PATIENT Act of 2023</b></p> <p>This bill delays a change to the payment methodology under Medicare for oral drugs that are used to treat end-stage renal disease (ESRD).</p> <p>Under current regulations, beginning January 1, 2025, the Centers for Medicare &amp; Medicaid Services will incorporate payments for oral-only ESRD drugs into the ESRD prospective payment system rather than issuing separate payments to ESRD facilities. The bill delays implementation of this policy until January 1, 2033, or until an approved intravenous drug is available, whichever is earlier.</p>

tv_txt: I 118th CONGRESS 1st Session H. R. 5074 IN THE HOUSE OF REPRESENTATIVES July 28, 2023 Mr. Carter of Georgia (for himself, Ms. Kuster , Mrs. Miller of West Virginia , and Ms. Sewell ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.

1. Short title This Act may be cited as the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 or the Kidney PATIENT Act of 2023 . 2. Delay of implementation of oral-only policy under Medicare ESRD prospective payment system Section 632(b) of the American Taxpayer Relief Act of 2012 ( 42 U.S.C. 1395rr note) is amended— (1) in the heading, by striking Two-year ; and (2) in the first sentence of paragraph (1), by striking may not implement and all that follows through January 1, 2025. and inserting shall not implement the policy under section 413.174(f)(6) of title 42, Code of Federal Regulations (relating to oral-only ESRD-related drugs in the ESRD prospective payment system) to incorporate the payment for oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual, until the earlier of January 1, 2033, or such time as an intravenous drug indicated for the reduction, management, or control of the serum phosphate of an individual has been approved by the Food and Drug Administration. .